Analysts Anticipate Aclaris Therapeutics Inc (ACRS) Will Announce Quarterly Sales of $800,000.00
Analysts forecast that Aclaris Therapeutics Inc (NASDAQ:ACRS) will post sales of $800,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Aclaris Therapeutics’ earnings. The lowest sales estimate is $600,000.00 and the highest is $1.00 million. The business is scheduled to report its next earnings results on Wednesday, March 21st.
According to Zacks, analysts expect that Aclaris Therapeutics will report full year sales of $800,000.00 for the current year, with estimates ranging from $680,000.00 to $1.68 million. For the next year, analysts forecast that the firm will report sales of $23.55 million per share, with estimates ranging from $18.58 million to $28.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Aclaris Therapeutics.
Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.86) by $0.23. The company had revenue of $0.68 million during the quarter, compared to the consensus estimate of $2.00 million.
Aclaris Therapeutics (ACRS) opened at $22.27 on Friday. Aclaris Therapeutics has a twelve month low of $21.47 and a twelve month high of $33.25.
Several institutional investors have recently made changes to their positions in ACRS. Eagle Asset Management Inc. boosted its stake in shares of Aclaris Therapeutics by 287.3% in the 2nd quarter. Eagle Asset Management Inc. now owns 1,357,973 shares of the biotechnology company’s stock valued at $36,828,000 after purchasing an additional 1,007,343 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Aclaris Therapeutics by 55.4% in the 2nd quarter. Franklin Resources Inc. now owns 1,955,381 shares of the biotechnology company’s stock valued at $53,030,000 after purchasing an additional 697,104 shares in the last quarter. Westfield Capital Management Co. LP boosted its position in Aclaris Therapeutics by 79.6% during the 2nd quarter. Westfield Capital Management Co. LP now owns 1,249,254 shares of the biotechnology company’s stock valued at $33,880,000 after buying an additional 553,752 shares during the period. FMR LLC boosted its position in Aclaris Therapeutics by 14.6% during the 2nd quarter. FMR LLC now owns 1,896,206 shares of the biotechnology company’s stock valued at $51,425,000 after buying an additional 242,269 shares during the period. Finally, Nexthera Capital LP boosted its position in Aclaris Therapeutics by 204.9% during the 2nd quarter. Nexthera Capital LP now owns 340,000 shares of the biotechnology company’s stock valued at $9,221,000 after buying an additional 228,500 shares during the period. 92.10% of the stock is owned by institutional investors.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.